SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Chet Gandhi as chief information officer. Mr. Gandhi brings a wealth of experience in leading and executing software and information technology strategies to enable the growth of global public and private companies.
“With a strong track record of success, Chet's expertise will play a crucial role in driving automation and supporting Twist's expansion efforts as we strive to grow our customer base from over three thousand to over one hundred thousand,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Having the appropriate software systems in place increases efficiency and serves both employees and customers. Chet's extensive experience in software and technology systems will be invaluable as we continue to execute our plans and prepare for the expected launch of fast genes in the fall.”
“I am excited to join Twist Bioscience, a company whose customers are dedicated to making a positive impact in health and sustainability,” said Mr. Gandhi. “Throughout my career, I have used technology to enable scalable growth by elevating the customer experience as well as enhancing and automating internal operations. I look forward to further supporting Twist's mission of changing the world for the better.”
Mr. Gandhi's areas of expertise include cloud computing, application and solution architecture, cybersecurity, artificial intelligence and data analytics. Prior to joining Twist, Mr. Gandhi served as chief information officer at Wineshipping, where he successfully led the company’s transformation from logistics to a technology-driven organization, optimizing the technology stack, enhancing the consumer experience, and driving internal efficiency. Previously, he held key leadership positions including vice president and global head of IT at Intapp and chief information officer and head of technology at Magento Commerce (acquired by Adobe). He also held a series of progressively responsible roles at Applied Micro Circuits. Mr. Gandhi holds a master’s of applied science in engineering from the University of British Columbia and a bachelor’s in technology from the Indian Institute of Technology.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Bioscience Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Twist Bioscience's expected expansion plans and introduction of new products. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s workforce reduction, transition of production to the Factory of the Future and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
